1. Home
  2. PAMT vs AGEN Comparison

PAMT vs AGEN Comparison

Compare PAMT & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PAMT CORP

PAMT

PAMT CORP

N/A

Current Price

$11.87

Market Cap

275.4M

Sector

Industrials

ML Signal

N/A

Logo Agenus Inc.

AGEN

Agenus Inc.

N/A

Current Price

$8.33

Market Cap

274.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PAMT
AGEN
Founded
1980
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Trucking Freight/Courier Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
275.4M
274.8M
IPO Year
1995
1999

Fundamental Metrics

Financial Performance
Metric
PAMT
AGEN
Price
$11.87
$8.33
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
★ $26.33
AVG Volume (30 Days)
12.3K
★ 960.9K
Earning Date
10-27-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 100.00
EPS
N/A
★ 0.96
Revenue
★ $437,838,000.00
$42,877,086.00
Revenue This Year
$17.76
$9.64
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
$10.30
Revenue Growth
1.15
★ 89.95
52 Week Low
$7.15
$2.71
52 Week High
$17.75
$10.06

Technical Indicators

Market Signals
Indicator
PAMT
AGEN
Relative Strength Index (RSI) 39.33 N/A
Support Level $10.72 N/A
Resistance Level $13.04 N/A
Average True Range (ATR) 0.80 0.00
MACD -0.01 0.00
Stochastic Oscillator 15.83 0.00

Price Performance

Historical Comparison
PAMT
AGEN

About PAMT PAMT CORP

PAMT Corp is a holding company that is engaged in providing truckload dry van carrier services transporting general commodities throughout the continental United States and Mexico, as well as in certain Canadian provinces. Its freight consists of automotive parts, expedited goods, consumer goods, such as general retail store merchandise, and manufactured goods, such as heating and air conditioning units. It has one reportable segment being motor carrier.

About AGEN Agenus Inc.

Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.

Share on Social Networks: